Sun Pharma Gets SEC Nod to Conduct Phase III Trial of Resmetirom Tablets
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended allowing Sun Pharma Laboratories Ltd. to conduct a Phase III clinical trial of Resmetirom tablets 60 mg, 80 mg and 100 mg.
According to the minutes, the company presented its proposal seeking permission to manufacture and market Resmetirom tablets in three strengths, along with a bioequivalence (BE) study report and Phase III clinical trial protocol, before the committee.
“After detailed deliberation, the committee considered the BE study results of Resmetirom Tablets 100 mg and recommended for grant of permission to conduct Phase III clinical trial of Resmetirom 60 mg, 80 mg and 100 mg as per protocol presented by the firm (Protocol No- ICR/25/013, Version No-1.0 dated 09.06.2025). Accordingly, the firm should submit Phase III clinical trial report to CDSCO for further review by the committee,” the minutes stated.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.